Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-7b9c58cd5d-7g5wt Total loading time: 0 Render date: 2025-03-15T13:12:04.685Z Has data issue: false hasContentIssue false

Chapter 6 - Hormone Therapy and Contraception Management

Published online by Cambridge University Press:  23 October 2024

By
Fionán Donohoe ,
Donal Brennan  and
Martha Hickey
Edited by
Laurie J. Mckenzie  and
Denise R. Nebgen
Laurie J. Mckenzie
Affiliation:
University of Texas MD Anderson Cancer Center, Houston
Denise R. Nebgen
Affiliation:
University of Texas MD Anderson Cancer Center, Houston
Get access

Summary

Cancer treatments can induce temporary or permanent menopause and lead to persistent menopausal symptoms. In reproductive age women, cancer treatment may impair fertility but evaluating fertility and managing contraception can be complex. Managing menopausal symptoms and contraceptive decisions after cancer treatment can be challenging for women and their care providers. In this chapter, we present concepts for managing these consultations and some specific advice for women in particular situations.

Keywords

CancerMenopauseContraceptionWomen’s HealthHRT
Type
Chapter
Information
Caring for the Female Cancer Patient
Gynecologic Considerations
 , pp. 93 - 106
Publisher: Cambridge University Press
Print publication year: 2024

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Harlow, S. D., Gass, M., Hall, J. E., et al. Executive summary of the Stages of Reproductive Aging Workshop + 10: Addressing the unfinished agenda of staging reproductive aging. Menopause. 2012;19(4):387–95.Google ScholarPubMed
Hickey, M., Hunter, M. S., Santoro, N., Ussher, J. Normalising menopause. BMJ. 2022;377:e069369.CrossRefGoogle ScholarPubMed
“The 2022 Hormone Therapy Position Statement of The North American Menopause Society” Advisory Panel. The 2022 hormone therapy position statement of The North American Menopause Society. Menopause. 2022;29(7):767–94.Google Scholar
Lethaby, A., Ayeleke, R. O., Roberts, H. Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database Syst Rev. 2016; 31(8):CD001500.Google Scholar
Haines, C. J., Xing, S. M., Park, K. H., Holinka, C. F., Ausmanas, M. K. Prevalence of menopausal symptoms in different ethnic groups of Asian women and responsiveness to therapy with three doses of conjugated estrogens/medroxyprogesterone acetate: The Pan-Asia Menopause (PAM) study. Maturitas. 2005;52(3–4):264–76.CrossRefGoogle ScholarPubMed
Anderson, R. A., Cameron, D., Clatot, F., et al. Anti-Müllerian hormone as a marker of ovarian reserve and premature ovarian insufficiency in children and women with cancer: A systematic review. Hum Reprod Update. 2022;28(3):417–34.CrossRefGoogle ScholarPubMed
Hickey, M., Szabo, R. A., Hunter, M. S. Non-hormonal treatments for menopausal symptoms. BMJ (Clinical research ed). 2017;23(359):j5101.CrossRefGoogle Scholar
Davis, S. R., Baber, R., Panay, N., et al. Global consensus position statement on the use of testosterone therapy for women. J Clin Endocrinol Metab. 2019;104(10):4660–6.CrossRefGoogle ScholarPubMed
Sturgeon, K. M., Deng, L., Bluethmann, S. M., et al. A population-based study of cardiovascular disease mortality risk in US cancer patients. Eur Heart J. 2019;40(48):3889–97.CrossRefGoogle ScholarPubMed
Zhu, D., Chung, H. F., Dobson, A. J., et al. Type of menopause, age of menopause and variations in the risk of incident cardiovascular disease: Pooled analysis of individual data from 10 international studies. Hum Reprod. 2020;35(8):1933–43.CrossRefGoogle ScholarPubMed
Scarabin, P. Y. Progestogens and venous thromboembolism in menopausal women: An updated oral versus transdermal estrogen meta-analysis. Climacteric. 2018;21(4):341–5.CrossRefGoogle ScholarPubMed
Canonico, M., Fournier, A., Carcaillon, L., et al. Postmenopausal hormone therapy and risk of idiopathic venous thromboembolism: Results from the E3 N cohort study. Arterioscler Thromb Vasc Biol. 2010;30(2):340–5.CrossRefGoogle Scholar
Elkins, G. R., Fisher, W. I., Johnson, A. K., Carpenter, J. S., Keith, T. Z. Clinical hypnosis in the treatment of postmenopausal hot flashes: A randomized controlled trial. Menopause. 2013;20(3):291–8.Google ScholarPubMed
Elkins, G., Marcus, J., Stearns, V., et al. Randomized trial of a hypnosis intervention for treatment of hot flashes among breast cancer survivors. J Clin Oncol. 2008;26(31):5022–6.CrossRefGoogle ScholarPubMed
Mann, E., Smith, M. J., Hellier, J., et al. Cognitive behavioural treatment for women who have menopausal symptoms after breast cancer treatment (MENOS 1): A randomised controlled trial. The Lancet Oncology. 2012;13(3):309–18.CrossRefGoogle ScholarPubMed
Green, S. M., Donegan, E., Frey, B. N., et al. Cognitive behavior therapy for menopausal symptoms (CBT-Meno): A randomized controlled trial. Menopause. 2019;26(9):972–80.Google ScholarPubMed
Guthrie, K. A., Larson, J. C., Ensrud, K. E., et al. Effects of pharmacologic and nonpharmacologic interventions on insomnia symptoms and self-reported sleep quality in women with hot flashes: A pooled analysis of individual participant data from four MsFLASH trials. Sleep. 2018 01;41(1).CrossRefGoogle ScholarPubMed
Kauffman, R. P. Telephone-based CBT reduced insomnia severity more than menopause education in menopausal women. Ann Intern Med. 2016;165(6):JC30.CrossRefGoogle ScholarPubMed
Franzoi, M. A., Agostinetto, E., Perachino, M., et al. Evidence-based approaches for the management of side-effects of adjuvant endocrine therapy in patients with breast cancer. Lancet Oncol. 2021;22(7):e303–13.CrossRefGoogle ScholarPubMed
Pinkerton, J. V., Abraham, L., Bushmakin, A. G., Cappelleri, J. C., Komm, B. S. Relationship between changes in vasomotor symptoms and changes in menopause-specific quality of life and sleep parameters. Menopause (New York, NY). 2016;23(10):1060–6.Google ScholarPubMed
Saadati, N., Mohammadjafari, R., Natanj, S., Abedi, P. The effect of gabapentin on intensity and duration of hot flashes in postmenopausal women: A randomized controlled trial. Glob J Health Sci. 2013;5(6):126–30.CrossRefGoogle ScholarPubMed
Modi, M., Dhillo, W. S. Neurokinin 3 receptor antagonism: A novel treatment for menopausal hot flushes. Neuroendocrinology. 2019;109(3):242–8.CrossRefGoogle ScholarPubMed
O’Meara, E. S., Rossing, M. A., Daling, J. R., et al. Hormone replacement therapy after a diagnosis of breast cancer in relation to recurrence and mortality. J Natl Cancer Inst. 2001;93(10):754–62.Google ScholarPubMed
Ponzone, R., Biglia, N., Jacomuzzi, M. E., et al. Vaginal oestrogen therapy after breast cancer: Is it safe? Eur J Cancer. 2005;41(17):2673–81.CrossRefGoogle ScholarPubMed
Stuenkel, C. A., Davis, S. R., Gompel, A., et al. Treatment of symptoms of the menopause: An Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2015;100(11):3975–4011.CrossRefGoogle ScholarPubMed
Dew, J. E., Wren, B. G., Eden, J. A. A cohort study of topical vaginal estrogen therapy in women previously treated for breast cancer. Climacteric. 2003;6(1):45–52.CrossRefGoogle ScholarPubMed
Le Ray, I., Dell’Aniello, S., Bonnetain, F., Azoulay, L., Suissa, S. Local estrogen therapy and risk of breast cancer recurrence among hormone-treated patients: A nested case-control study. Breast Cancer Res Treat. 2012;135(2):603–9.CrossRefGoogle ScholarPubMed
Melisko, M. E., Goldman, M. E., Hwang, J., et al. Vaginal testosterone cream vs estradiol vaginal ring for vaginal dryness or decreased libido in women receiving aromatase inhibitors for early-stage breast cancer: A randomized clinical trial. JAMA Oncol. 2017;3(3):313–19.CrossRefGoogle ScholarPubMed
Wills, S., Ravipati, A., Venuturumilli, P., et al. Effects of vaginal estrogens on serum estradiol levels in postmenopausal breast cancer survivors and women at risk of breast cancer taking an aromatase inhibitor or a selective estrogen receptor modulator. J Oncol Pract. 2012;8(3):144–8.CrossRefGoogle ScholarPubMed
Brennan, A., Brennan, D., Rees, M., Hickey, M. Management of menopausal symptoms and ovarian function preservation in women with gynecological cancer. International Journal of Gynecologic Cancer [Internet]. 2021;31(3). https://ijgc.bmj.com/content/31/3/352CrossRefGoogle ScholarPubMed
Edwards, D., Panay, N. Treating vulvovaginal atrophy/genitourinary syndrome of menopause: How important is vaginal lubricant and moisturizer composition? Climacteric. 2016;19(2):151–61.CrossRefGoogle ScholarPubMed
Mitchell, C. M., Reed, S. D., Diem, S., et al. Efficacy of vaginal estradiol or vaginal moisturizer vs placebo for treating postmenopausal vulvovaginal symptoms: A randomized clinical trial. JAMA Intern Med. 2018;178(5):681–90.CrossRefGoogle ScholarPubMed
Chan, J. A., Meyerhardt, J. A., Chan, A. T., et al. Hormone replacement therapy and survival after colorectal cancer diagnosis. J Clin Oncol. 2006;24(36):5680–6.CrossRefGoogle ScholarPubMed
Calle, E. E., Miracle-McMahill, H. L., Thun, M. J., Heath, C. W. Estrogen replacement therapy and risk of fatal colon cancer in a prospective cohort of postmenopausal women. J Natl Cancer Inst. 1995;87(7):517–23.CrossRefGoogle Scholar
Mahase, E. Colorectal cancer: Screening may need to change given rising incidence in under 50s. BMJ. 2019 May 17;365:l2249.CrossRefGoogle ScholarPubMed
Tauchmanovà, L., Selleri, C., De Rosa, G., et al. Estrogen-progestin therapy in women after stem cell transplant: Our experience and literature review. Menopause. 2007;14(2):320–30.Google ScholarPubMed
Holmberg, L., Iversen, O. E., Rudenstam, C. M., et al. Increased risk of recurrence after hormone replacement therapy in breast cancer survivors. J Natl Cancer Inst. 2008;100(7):475–82.CrossRefGoogle ScholarPubMed
von Schoultz, E., Rutqvist, L. E., Stockholm Breast Cancer Study Group. Menopausal hormone therapy after breast cancer: The Stockholm randomized trial. J Natl Cancer Inst. 2005;97(7):533–5.CrossRefGoogle Scholar
Kenemans, P., Bundred, N. J., Foidart, J. M., et al. Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: A double-blind, randomised, non-inferiority trial. Lancet Oncol. 2009;10(2):135–46.CrossRefGoogle ScholarPubMed
Poggio, F., Del Mastro, L., Bruzzone, M., et al. Safety of systemic hormone replacement therapy in breast cancer survivors: A systematic review and meta-analysis. Breast Cancer Res Treat. 2022;191(2):269–75.CrossRefGoogle ScholarPubMed
Edey, K. A., Rundle, S., Hickey, M. Hormone replacement therapy for women previously treated for endometrial cancer. Cochrane Database Syst Rev. 2018;5:CD008830.Google ScholarPubMed
Concin, N., Matias-Guiu, X., Vergote, I., et al. ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. International Journal of Gynecologic Cancer. 2020;ijgc.Google Scholar
Pergialiotis, V., Pitsouni, E., Prodromidou, A., et al. Hormone therapy for ovarian cancer survivors: Systematic review and meta-analysis. Menopause. 2016;23(3):335–42.Google ScholarPubMed
Li, D., Ding, C. Y., Qiu, L. H. Postoperative hormone replacement therapy for epithelial ovarian cancer patients: A systematic review and meta-analysis. Gynecol Oncol. 2015;139(2):355–62.CrossRefGoogle ScholarPubMed
45. MacKie, R. M., Bray, C. A. Hormone replacement therapy after surgery for stage 1 or 2 cutaneous melanoma. Br J Cancer. 2004;90(4):770–2.CrossRefGoogle ScholarPubMed
Clague, J., Reynolds, P., Henderson, K. D., et al. Menopausal hormone therapy and lung cancer-specific mortality following diagnosis: The California Teachers Study. PLoS One. 2014;9(7):e103735.CrossRefGoogle ScholarPubMed
Katcoff, H., Wenzlaff, A. S., Schwartz, A. G. Survival in women with NSCLC: The role of reproductive history and hormone use. J Thorac Oncol. 2014;9(3):355–61.CrossRefGoogle ScholarPubMed
Ganti, A. K., Sahmoun, A. E., Panwalkar, A. W., Tendulkar, K. K., Potti, A. Hormone replacement therapy is associated with decreased survival in women with lung cancer. J Clin Oncol. 2006;24(1):59–63.CrossRefGoogle ScholarPubMed
Chlebowski, R. T., Schwartz, A. G., Wakelee, H., et al. Oestrogen plus progestin and lung cancer in postmenopausal women (Women’s Health Initiative trial): A post-hoc analysis of a randomised controlled trial. Lancet. 2009;374(9697):1243–51.CrossRefGoogle Scholar
Kotsopoulos, J., Gronwald, J., Karlan, B. Y., et al. Hormone replacement therapy after oophorectomy and breast cancer risk among BRCA1 mutation carriers. JAMA Oncol. 2018;4(8):1059–65.CrossRefGoogle ScholarPubMed
Gordhandas, S., Norquist, B. M., Pennington, K. P., et al. Hormone replacement therapy after risk reducing salpingo-oophorectomy in patients with BRCA1 or BRCA2 mutations: A systematic review of risks and benefits. Gynecol Oncol. 2019;153(1):192–200.CrossRefGoogle ScholarPubMed
Siegel, R. L., Miller, K. D., Fuchs, H. E., Jemal, A. Cancer statistics, 2021. CA: A Cancer Journal for Clinicians. 2021;71(1):7–33.Google Scholar
Quinn, M. M., Letourneau, J. M., Rosen, M. P. Contraception after cancer treatment: describing methods, counseling, and unintended pregnancy risk. Contraception. 2014;89(5):466–71.CrossRefGoogle ScholarPubMed
Hadnott, T. N., Stark, S. S., Medica, A., et al. Perceived infertility and contraceptive use in the female, reproductive-age cancer survivor. Fertil Steril. 2019;111(4):763–71.CrossRefGoogle ScholarPubMed
Dominick, S. A., McLean, M. R., Whitcomb, B. W., et al. Contraceptive practices among female cancer survivors of reproductive age. Obstet Gynecol. 2015;126(3):498–507.CrossRefGoogle ScholarPubMed
World Health Organization. Medical eligibility criteria for contraceptive use (MEC). World Health Organization; 2015.Google Scholar
Romero, S. A., Young, K., Hickey, M., Su, H. I. Levonorgestrel intrauterine system for endometrial protection in women with breast cancer on adjuvant tamoxifen. Cochrane Database Syst Rev. 2020;12:CD007245.Google ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure [email protected] is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×